Peptide hormone (51-amino-acid disulfide-linked dipeptide)

Our opinion on this compoundResearch workhorse

52/100

Canonical metabolic reference probe with irreplaceable bench utility but near-zero novelty

Look, there is no compound in biology more foundational than insulin. Banting and Best cracked it in 1921. The receptor was cloned, the IRS-1/2 scaffolding was mapped, the PI3K-Akt axis was traced to GLUT4 translocation, and the whole signaling story was essentially complete by the mid-1990s. From a novelty standpoint this scores at the floor. We’re not being harsh; thats just the reality of a 100-year-old Nobel Prize molecule.

What keeps insulin interesting as a research tool is the same thing that keeps it from being a frontier compound: its centrality. If you’re running any experiment touching glucose uptake, anabolic signaling, or metabolic flux, you’re almost certainly using insulin as the reference stimulus or the positive control. There’s no substitute. The IGF-1R cross-talk is relevant for cancer metabolism work, and the PI3K/Akt/mTOR axis that insulin activates sits upstream of half the longevity and senescence biology being done right now. So bench value here is genuinely high. But insulin is the reference, not the question.

Here’s the honest picture for a research team: the evidence quality and translational signal are as strong as they get. This is an approved therapeutic with over a century of replicated human data and a fully characterized, essential mechanism. But thats actually the problem for research prioritization. When something is this well-understood, you’re not learning new biology from the compound itself; you’re using it as a tool to probe other things. That use case is real and important, but it isn’t where the frontier is.

We think insulin occupies a specific, defensible niche: the essential stimulus compound for anyone working on IR biology, GLUT4 trafficking, PI3K-Akt signaling in cancer or longevity contexts, or any assay that needs a defined, clean anabolic signal. For those programs, you can’t replace it. What we don’t think is that insulin should be the primary research target for a forward-looking program, because the interesting biology has moved to receptor analogs, biased agonists, and dual-signaling molecules that do things insulin itself doesn’t do.

One operational note worth flagging: the hypoglycemia risk is acute and serious, and institutional protocols for in vivo insulin work are non-trivial. That doesn’t change the score, but it’s a real consideration for bench setup. Ultimately a low-50s score here is exactly right: genuine irreplaceable utility and unimpeachable evidence pull it up; the complete absence of new mechanism or frontier signal pull it firmly away from the compounds investigators should be prioritizing.

Novelty: 12
Mechanism promise: 22
In-category differentiation: 58
Evidence quality: 88
Translational signal: 88
Research bench value: 75

Rationale Insulin scores at the floor on novelty and mechanism (fully mapped since the mid-1990s, no new biology to find in the compound itself) but its evidence base and translational signal are essentially perfect, and its bench value as the irreplaceable reference standard for IR/PI3K-Akt work keeps it from collapsing. Low-50s overall reflects a foundational workhorse that researchers use to ask questions about other things, not a frontier compound.

Peptide hormone (51-amino-acid disulfide-linked dipeptide)

The pancreatic peptide hormone insulin; the foundational glucose-regulatory hormone and a research probe for metabolic and anabolic biology.

Abstract

Insulin (CAS 9004-10-8; A-chain 21 amino acids, B-chain 30 amino acids; total molecular weight approximately 5808 Da for human insulin) is the pancreatic peptide hormone discovered by Banting and Best in 1921 (Nobel Prize 1923) and synthesized as recombinant human insulin (Humulin) in 1982 by Genentech, the first FDA-approved recombinant pharmaceutical. Pharmacologically, insulin binds the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) with substantially higher affinity for IR. Receptor binding triggers tyrosine kinase activation of IRS-1/2 and downstream PI3K-Akt signaling, regulating glucose uptake (GLUT4 translocation), glycogen synthesis, lipogenesis, and protein synthesis. Modern formulations include rapid-acting analogs (lispro, aspart, glulisine), regular insulin, intermediate (NPH), long-acting (glargine, detemir, degludec), and ultra-long-acting (degludec). Approved indications: type 1 diabetes (essential), type 2 diabetes (when oral agents fail). The principal safety risk is hypoglycemia, severe enough to cause neuronal injury or death; insulin is among the leading drug-related causes of medical emergency department visits. Recreational anabolic use has been documented but is associated with high acute mortality. Used as the canonical metabolic hormone in academic biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-292Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Peptide hormone (51-amino-acid disulfide-linked dipeptide)

Insulin (Research)

Abstract

Read the full monograph